06 May 2021 (Last Updated May 6th, 2021 12:37)
Ortho Clinical Diagnostics has received CE mark for the new VITROS Anti-SARS-CoV-2 IgG Quantitative (QN) Antibody assay designed to offer values in line with the World Health Organisation (WHO) International Standard.
Share Article
The company intends to produce up to eight million quantitative IgG antibody tests monthly. Credit: Andreas Lischka from Pixabay.
The WHO standardisation aids in regulating Covid-19 virus serological methods and permits unified data comparison across labs.
The new assay is indicated for the qualitative and quantitative identification of IgG antibodies to SARS-CoV-2 in human serum and plasma.
The test will facilitate analysis of a person’s immune response level on being infected with the SARS-CoV-2 virus or on receiving a vaccination. It will serve as a standardised tool for public health workers to assess changes in the antibody levels of Covid-19 patient
Operator
Good day, and thank you for standing by. Welcome to the Ortho Clinical Diagnostics quarter one 2021 earnings conference call. [Operator instructions] I would now like to hand the conference over to your first our first speaker for today, Mr. John Sanders, vice president of finance, treasurer, and head of investor relations.
Thank you. Please go ahead.
John Sanders
Vice President of Finance, Treasurer, and Head of Investor Relations
Thank you, Ann. And good afternoon, everyone. With me today to discuss our financial results are the chairman and CEO of Ortho Clinical Diagnostics, Chris Smith; and Joe Busky, Ortho s chief financial officer; Mike Iskra, our EVP of commercial excellence and strategy, will join us on the Q&A portion of the call. This conference call is being simultaneously webcast on the Investors section of our website, and a version of today s presentation can be downloaded there.
Secondary Research, Primary Research, Company Share Analysis, Model ( including Macro-monetary pointers, Demographic information, and Industry pointers: Expenditure, foundation, area development, and offices ), Research Limitations and Revenue Based Modeling. Organization share examination is utilized to determine the size of the worldwide market. Just as an investigation of incomes of organizations for the last three to five years likewise gives the base to determine the market size and Shares (2021-2027 ) and its development rate. also, representing the Clinical Diagnostics Market Factor Analysis-
Porter’s Five Forces, Supply/Value Chain, PESTEL analysis, CAGR value, product offerings, company landscape analysis, Market Entropy, CAPEX cycle, COGS Analysis, EBITDA analysis, Patent/Trademark Analysis, and Post COVID Impact Analysis. Key Leading Players having extreme Growth Rate in last Few decades included